Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy.

Cao Y, Chang Q, Zhang W, Ornatsky O, Hedley D, Chen EX.

Cancer Chemother Pharmacol. 2019 Sep 13. doi: 10.1007/s00280-019-03956-6. [Epub ahead of print]

PMID:
31520102
2.

A wide pH-range stable crystalline framework based on the largest tin-oxysulfide cluster [Sn20O10S34].

Huang SL, He L, Chen EX, Lai HD, Zhang J, Lin Q.

Chem Commun (Camb). 2019 Sep 21;55(74):11083-11086. doi: 10.1039/c9cc05736f. Epub 2019 Aug 28.

PMID:
31460533
3.

An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.

Longo J, Mullen PJ, Yu R, van Leeuwen JE, Masoomian M, Woon DTS, Wang Y, Chen EX, Hamilton RJ, Sweet JM, van der Kwast TH, Fleshner NE, Penn LZ.

Mol Metab. 2019 Jul;25:119-130. doi: 10.1016/j.molmet.2019.04.003. Epub 2019 Apr 10.

4.

Robust Porphyrin-Spaced Zirconium Pyrogallate Frameworks with High Proton Conduction.

Chen EX, Xu G, Lin Q.

Inorg Chem. 2019 Mar 18;58(6):3569-3573. doi: 10.1021/acs.inorgchem.8b03132. Epub 2019 Feb 28.

PMID:
30816707
5.

Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas.

Sim HW, Nejad R, Zhang W, Nassiri F, Mason W, Aldape KD, Zadeh G, Chen EX.

Clin Cancer Res. 2019 Jun 1;25(11):3366-3373. doi: 10.1158/1078-0432.CCR-18-3205. Epub 2019 Feb 18.

PMID:
30777876
6.

Dual-cubic-cage based lanthanide sulfate-carboxylpyrazolate frameworks with high hydrolytic stability and remarkable proton conduction.

He L, Nath JK, Chen EX, Lai HD, Huang SL, Lin Q.

Chem Commun (Camb). 2019 Feb 21;55(17):2497-2500. doi: 10.1039/c8cc09474h.

PMID:
30741284
7.

Minimally Invasive Transforaminal Lumbar Interbody Fusion: 2-Dimensional Surgical Video.

McMordie JH, Chen EX, Ehlers LD, Gillis CC.

Oper Neurosurg (Hagerstown). 2019 Aug 1;17(2):E53. doi: 10.1093/ons/opy394.

PMID:
30629236
8.

Early predictors of hyperlipidemic acute pancreatitis.

Cao X, Wang HM, Du H, Chen EX, Yang XF, Wang SL, Ding Y, She ZF.

Exp Ther Med. 2018 Nov;16(5):4232-4238. doi: 10.3892/etm.2018.6713. Epub 2018 Sep 10.

9.

Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells.

Agnihotri S, Mansouri S, Burrell K, Li M, Mamatjan Y, Liu J, Nejad R, Kumar S, Jalali S, Singh SK, Vartanian A, Chen EX, Karimi S, Singh O, Bunda S, Mansouri A, Aldape KD, Zadeh G.

Clin Cancer Res. 2019 Jan 15;25(2):844-855. doi: 10.1158/1078-0432.CCR-18-1854. Epub 2018 Oct 15.

PMID:
30322879
10.

The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy.

Hosni A, Han K, Le LW, Ringash J, Brierley J, Wong R, Dinniwell R, Brade A, Dawson LA, Cummings BJ, Krzyzanowska MK, Chen EX, Hedley D, Knox J, Easson AM, Lindsay P, Craig T, Kim J.

Oncotarget. 2018 Apr 17;9(29):20439-20450. doi: 10.18632/oncotarget.24926. eCollection 2018 Apr 17.

11.

Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort.

Bernstein LJ, Pond GR, Gan HK, Tirona K, Chan KK, Hope A, Kim J, Chen EX, Siu LL, Razak ARA.

Head Neck. 2018 Sep;40(9):2029-2042. doi: 10.1002/hed.25198. Epub 2018 Apr 17.

PMID:
29667262
12.

A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.

Jonker DJ, Tang PA, Kennecke H, Welch SA, Cripps MC, Asmis T, Chalchal H, Tomiak A, Lim H, Ko YJ, Chen EX, Alcindor T, Goffin JR, Korpanty GJ, Feilotter H, Tsao MS, Theis A, Tu D, Seymour L.

Clin Colorectal Cancer. 2018 Sep;17(3):231-239.e7. doi: 10.1016/j.clcc.2018.03.001. Epub 2018 Mar 8.

PMID:
29653857
13.

Acid and Base Resistant Zirconium Polyphenolate-Metalloporphyrin Scaffolds for Efficient CO2 Photoreduction.

Chen EX, Qiu M, Zhang YF, Zhu YS, Liu LY, Sun YY, Bu X, Zhang J, Lin Q.

Adv Mater. 2018 Jan;30(2). doi: 10.1002/adma.201704388. Epub 2017 Nov 27.

PMID:
29178432
14.

Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer.

Zer A, Pond GR, Razak ARA, Tirona K, Gan HK, Chen EX, O'Sullivan B, Waldron J, Goldstein DP, Weinreb I, Hope AJ, Kim JJ, Chan KKW, Chan AK, Siu LL, Bernstein LJ.

JAMA Otolaryngol Head Neck Surg. 2018 Jan 1;144(1):71-79. doi: 10.1001/jamaoto.2017.2235.

15.

Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience.

Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, Liu G, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao MS, Zhang T, Yu C, Kamel-Reid S, Siu LL, Bedard PL, Chen EX.

Clin Colorectal Cancer. 2018 Mar;17(1):73-79. doi: 10.1016/j.clcc.2017.10.010. Epub 2017 Oct 23.

PMID:
29128266
16.

Coded Apertures in Mass Spectrometry.

Amsden JJ, Gehm ME, Russell ZE, Chen EX, Di Dona ST, Wolter SD, Danell RM, Kibelka G, Parker CB, Stoner BR, Brady DJ, Glass JT.

Annu Rev Anal Chem (Palo Alto Calif). 2017 Jun 12;10(1):141-156. doi: 10.1146/annurev-anchem-061516-045256. Epub 2017 Mar 6.

PMID:
28301752
17.

Increasing Stability of Biotin Functionalized Electrospun Fibers for Biosensor Applications.

Shepherd LM, González E, Chen EX, Frey MW.

ACS Appl Mater Interfaces. 2017 Jan 18;9(2):1968-1974. doi: 10.1021/acsami.6b14348. Epub 2017 Jan 4.

PMID:
27996235
18.

Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial.

Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, Hay JH, Ringash J, Liu G, Johnson A, Shenouda G, Chasen M, Pearce A, Butler JB, Breen S, Chen EX, FitzGerald TJ, Childs TJ, Montenegro A, O'Sullivan B, Parulekar WR.

JAMA Oncol. 2017 Feb 1;3(2):220-226. doi: 10.1001/jamaoncol.2016.4510.

PMID:
27930762
19.

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL.

Genome Med. 2016 Oct 25;8(1):109.

20.

Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).

Prawira A, Brana-Garcia I, Spreafico A, Hope A, Waldron J, Razak AR, Chen EX, Jang R, O'Sullivan B, Giuliani M, Bayley A, Cho J, Wang L, Perez-Ordonez B, Weinreb I, Siu LL, Hansen AR.

Invest New Drugs. 2016 Oct;34(5):575-83. doi: 10.1007/s10637-016-0367-2. Epub 2016 Jun 11.

PMID:
27289242
21.

A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.

Chen EX, Jonker DJ, Siu LL, McKeever K, Keller D, Wells J, Hagerman L, Seymour L.

Invest New Drugs. 2016 Aug;34(4):450-7. doi: 10.1007/s10637-016-0351-x. Epub 2016 Apr 13.

PMID:
27075016
22.

Synthesis of borocarbonitride from a multifunctional Cu(I) boron imidazolate framework.

Wen T, Chen EX, Zhang DX, Zhang J.

Dalton Trans. 2016 Mar 28;45(12):5223-8. doi: 10.1039/c5dt04805b.

PMID:
26893036
23.

Order of Magnitude Signal Gain in Magnetic Sector Mass Spectrometry Via Aperture Coding.

Chen EX, Russell ZE, Amsden JJ, Wolter SD, Danell RM, Parker CB, Stoner BR, Gehm ME, Glass JT, Brady DJ.

J Am Soc Mass Spectrom. 2015 Sep;26(9):1633-40. doi: 10.1007/s13361-015-1178-y. Epub 2015 Jun 26.

PMID:
26111517
24.
25.
26.

Identification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinoma.

Bruce JP, Hui AB, Shi W, Perez-Ordonez B, Weinreb I, Xu W, Haibe-Kains B, Waggott DM, Boutros PC, O'Sullivan B, Waldron J, Huang SH, Chen EX, Gilbert R, Liu FF.

Oncotarget. 2015 Feb 28;6(6):4537-50.

27.

A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.

How J, Minden MD, Brian L, Chen EX, Brandwein J, Schuh AC, Schimmer AD, Gupta V, Webster S, Degelder T, Haines P, Stayner LA, McGill S, Wang L, Piekarz R, Wong T, Siu LL, Espinoza-Delgado I, Holleran JL, Egorin MJ, Yee KW.

Leuk Lymphoma. 2015;56(10):2793-802. doi: 10.3109/10428194.2015.1018248. Epub 2015 Mar 30.

28.

Two-dimensional aperture coding for magnetic sector mass spectrometry.

Russell ZE, Chen EX, Amsden JJ, Wolter SD, Danell RM, Parker CB, Stoner BR, Gehm ME, Brady DJ, Glass JT.

J Am Soc Mass Spectrom. 2015 Feb;26(2):248-56. doi: 10.1007/s13361-014-1051-4. Epub 2014 Dec 16.

PMID:
25510933
29.

Highly selective and sensitive trimethylamine gas sensor based on cobalt imidazolate framework material.

Chen EX, Fu HR, Lin R, Tan YX, Zhang J.

ACS Appl Mater Interfaces. 2014 Dec 24;6(24):22871-5. doi: 10.1021/am5071317. Epub 2014 Dec 3.

PMID:
25420211
30.

A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.

Chen EX, Hotte S, Hirte H, Siu LL, Lyons J, Squires M, Lovell S, Turner S, McIntosh L, Seymour L.

Br J Cancer. 2014 Dec 9;111(12):2262-7. doi: 10.1038/bjc.2014.565. Epub 2014 Nov 13.

31.

A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin.

Brana I, Ocana A, Chen EX, Razak AR, Haines C, Lee C, Douglas S, Wang L, Siu LL, Tannock IF, Bedard PL.

Invest New Drugs. 2014 Dec;32(6):1269-77. doi: 10.1007/s10637-014-0159-5. Epub 2014 Sep 12.

PMID:
25213162
32.

Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.

Han K, Cummings BJ, Lindsay P, Skliarenko J, Craig T, Le LW, Brierley J, Wong R, Dinniwell R, Bayley AJ, Dawson LA, Ringash J, Krzyzanowska MK, Moore MJ, Chen EX, Easson AM, Kassam Z, Cho C, Kim J.

Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):587-94. doi: 10.1016/j.ijrobp.2014.06.061. Epub 2014 Sep 3.

PMID:
25194664
33.

Factors associated with publication of randomized phase iii cancer trials in journals with a high impact factor.

Tang PA, Pond GR, Welch S, Chen EX.

Curr Oncol. 2014 Aug;21(4):e564-72. doi: 10.3747/co.21.1937.

34.

Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.

Loong HH, Winquist E, Waldron J, Chen EX, Kim J, Palma D, Read N, Razak AR, Diaz-Padilla I, Chan K, Bayley A, Hossain M, Wang L, Chin S, Siu LL, Hope A.

Eur J Cancer. 2014 Sep;50(13):2263-70. doi: 10.1016/j.ejca.2014.05.021. Epub 2014 Jun 19.

PMID:
24953566
35.

Zeolitic imidazolate framework as formaldehyde gas sensor.

Chen EX, Yang H, Zhang J.

Inorg Chem. 2014 Jun 2;53(11):5411-3. doi: 10.1021/ic500474j. Epub 2014 May 12.

PMID:
24813234
36.

Compressive mass analysis on quadrupole ion trap systems.

Chen EX, Gehm M, Danell R, Wells M, Glass JT, Brady D.

J Am Soc Mass Spectrom. 2014 Jul;25(7):1295-304. doi: 10.1007/s13361-014-0894-z. Epub 2014 May 8.

PMID:
24806048
37.

Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.

Ocean AJ, Christos P, Sparano JA, Shah MA, Yantiss RK, Cheng J, Lin J, Papetti M, Matulich D, Schnoll-Sussman F, Besanceney-Webler C, Xiang J, Ward M, Dilts KT, Keresztes R, Holloway S, Chen EX, Wright JJ, Lane ME.

Invest New Drugs. 2014 Jun;32(3):542-8. doi: 10.1007/s10637-014-0070-0. Epub 2014 Feb 15.

38.

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.

Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, Stockler MR, Lee CW, Chen EX, Montenegro A, Ding K, Bradbury PA.

Eur J Cancer. 2014 Mar;50(4):706-12. doi: 10.1016/j.ejca.2013.11.032. Epub 2013 Dec 17.

PMID:
24360368
39.

NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies.

Dent SF, Gelmon KA, Chi KN, Jonker DJ, Wainman N, Capier CA, Chen EX, Lyons JF, Seymour L.

Invest New Drugs. 2013 Dec;31(6):1522-9. doi: 10.1007/s10637-013-0018-9. Epub 2013 Sep 27.

PMID:
24072436
40.

Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review.

Péron J, Maillet D, Gan HK, Chen EX, You B.

J Clin Oncol. 2013 Nov 1;31(31):3957-63. doi: 10.1200/JCO.2013.49.3981. Epub 2013 Sep 23. Review.

PMID:
24062406
41.

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).

Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T, Kamel-Reid S, Chen H, Ivy SP, Razak AR, Oza AM, Chen EX, Hirte HW, McGarrity A, Wang L, Siu LL, Hotte SJ.

Br J Cancer. 2013 Aug 20;109(4):943-9. doi: 10.1038/bjc.2013.380. Epub 2013 Jul 18.

42.

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.

Diaz-Padilla I, Hirte H, Oza AM, Clarke BA, Cohen B, Reedjik M, Zhang T, Kamel-Reid S, Ivy SP, Hotte SJ, Razak AA, Chen EX, Brana I, Wizemann M, Wang L, Siu LL, Bedard PL.

Invest New Drugs. 2013 Oct;31(5):1182-91. doi: 10.1007/s10637-013-0001-5. Epub 2013 Jul 17.

43.

β-Receptor blocker influences return of spontaneous circulation and chemical examination in rats during cardiopulmonary resuscitation.

Zhao XJ, Pen Z, Li P, Chen EX, Liu J, Gao YX, Ren YX, Li LJ.

J Zhejiang Univ Sci B. 2013 Jun;14(6):505-10. doi: 10.1631/jzus.B1200293.

44.

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).

Richter S, Bedard PL, Chen EX, Clarke BA, Tran B, Hotte SJ, Stathis A, Hirte HW, Razak AR, Reedijk M, Chen Z, Cohen B, Zhang WJ, Wang L, Ivy SP, Moore MJ, Oza AM, Siu LL, McWhirter E.

Invest New Drugs. 2014 Apr;32(2):243-9. doi: 10.1007/s10637-013-9965-4. Epub 2013 May 5.

45.

In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours.

Quintela-Fandino M, Krzyzanowska M, Duncan G, Young A, Moore MJ, Chen EX, Stathis A, Colomer R, Petronis J, Grewal M, Webster S, Wang L, Siu LL.

Br J Cancer. 2013 Apr 2;108(6):1298-305. doi: 10.1038/bjc.2013.64. Epub 2013 Feb 14.

46.

A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.

Sridhar SS, Mackenzie MJ, Hotte SJ, Mukherjee SD, Tannock IF, Murray N, Kollmannsberger C, Haider MA, Chen EX, Halford R, Wang L, Ivy SP, Moore MJ.

Invest New Drugs. 2013 Aug;31(4):1008-15. doi: 10.1007/s10637-013-9931-1. Epub 2013 Jan 26.

PMID:
23354849
47.

Influence of statistician involvement on reporting of randomized clinical trials in medical oncology.

Péron J, You B, Gan HK, Maillet D, Chen EX, Pond GR.

Anticancer Drugs. 2013 Mar;24(3):306-9. doi: 10.1097/CAD.0b013e32835c3561.

PMID:
23221738
48.

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck.

Abdul Razak AR, Soulières D, Laurie SA, Hotte SJ, Singh S, Winquist E, Chia S, Le Tourneau C, Nguyen-Tan PF, Chen EX, Chan KK, Wang T, Giri N, Mormont C, Quinn S, Siu LL.

Ann Oncol. 2013 Mar;24(3):761-9. doi: 10.1093/annonc/mds503. Epub 2012 Oct 28.

PMID:
23108949
49.

[Consistency in the analysis and reporting of PEPs in oncology randomized controlled trials from registration to publication: a systematic review].

Boespflug A, Gan H, Chen EX, Pond G, You B.

Bull Cancer. 2012 Oct;99(10):943-52. doi: 10.1684/bdc.2012.1651. Review. French.

50.

Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review.

Péron J, Pond GR, Gan HK, Chen EX, Almufti R, Maillet D, You B.

J Natl Cancer Inst. 2012 Jul 3;104(13):982-9. doi: 10.1093/jnci/djs259. Epub 2012 Jul 3. Review.

PMID:
22761273

Supplemental Content

Support Center